ABCL vs MSFT: Which Stock is Better?
Side-by-side comparison of Abcellera Biologics Inc and Microsoft Corp in 2026
ABCL
Abcellera Biologics Inc
$4.16
MSFT
Microsoft Corp
$454.79
Key Metrics Comparison
| Metric | ABCL | MSFT | Winner |
|---|---|---|---|
| Market Cap | $1.23B | $3.38T | MSFT |
| P/E Ratio | N/A | 36.30 | MSFT |
| EPS (TTM) | $N/A | $13.70 | MSFT |
| Revenue Growth | 0.4% | 14.9% | MSFT |
| Gross Margin | -417.5% | 68.8% | MSFT |
Analyze ABCL
Full quant analysis
Analyze MSFT
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is ABCL or MSFT a better investment?
Comparing ABCL and MSFT: Abcellera Biologics Inc has a market cap of $1.23B while Microsoft Corp has $3.38T. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between ABCL and MSFT?
ABCL (Abcellera Biologics Inc) and MSFT (Microsoft Corp) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: ABCL or MSFT?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: ABCL or MSFT?
MSFT has higher revenue growth at 14.9% vs 0.4% for ABCL.
Which company is more profitable: ABCL or MSFT?
Microsoft Corp (MSFT) has higher gross margins at 68.8% compared to -417.5% for ABCL.
Which is the larger company: ABCL or MSFT?
Microsoft Corp (MSFT) is larger with a market cap of $3.38T compared to $1.23B for ABCL.
Should I buy ABCL or MSFT in 2026?
Both ABCL and MSFT have investment merit. ABCL trades at $4.16 while MSFT trades at $454.79. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between ABCL and MSFT stock?
Key differences: Market Cap ($1.23B vs $3.38T), P/E Ratio (N/A vs 36.3x), Revenue Growth (0.4% vs 14.9%), Gross Margin (-417.5% vs 68.8%).